HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mora, A. L. Articles by Tam, J. P. Search for Related Content PubMed PubMed Citation Articles by Mora, A. L. Articles by Tam, J. P. Pubmed/NCBI databases Substance via MeSH

Controlled Lipidation and Encapsulation of Peptides as a Useful Approach to Mucosal Immunizations¹

Department of Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232

To generate a useful strategy for mucosal immunization, we have developed an approach of lipidating a multiple Ag peptide (MAP) containing part of the V3 loop from HIV-1 gp120_IIIB. In this work, we compare two delivery systems, lipidated MAP in PBS and encapsulation in poly(DL-lactide-co-glycolide) microparticles. Subcutaneous immunization, followed by intragastric administration of MAP peptide entrapped or not entrapped in microparticles, induced mucosal and systemic immune responses at local and distant sites, including mucosal IgA in saliva, vaginal secretions and feces, and IgG in blood. However, lipidated Ag delivered in microparticles induced higher levels of mucosal Abs, particularly of intestinal IgA, and generated CTL responses. In contrast, lipidated MAP delivered by nasal route microparticles was less effective in inducing CTL responses. These results demonstrate the feasibility of using a lipidated multimeric peptide for mucosal immunization to stimulate both systemic and mucosal immune systems, including the genital tract, irrespective of the route or method of delivery and without requiring the use of a carrier or an extraneous adjuvant.

This article has been cited by other articles:

				T. Woodberry, T. J. Suscovich, L. M. Henry, M. August, M. T. Waring, A. Kaur, C. Hess, J. L. Kutok, J. C. Aster, F. Wang, et al. {alpha}E{beta}7 (CD103) Expression Identifies a Highly Active, Tonsil-Resident Effector-Memory CTL Population J. Immunol., October 1, 2005; 175(7): 4355 - 4362. [Abstract] [Full Text] [PDF]

				C. Olive, M. Batzloff, A. Horvath, T. Clair, P. Yarwood, I. Toth, and M. F. Good Potential of Lipid Core Peptide Technology as a Novel Self-Adjuvanting Vaccine Delivery System for Multiple Different Synthetic Peptide Immunogens Infect. Immun., May 1, 2003; 71(5): 2373 - 2383. [Abstract] [Full Text] [PDF]

				C. La Rosa, Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice Blood, November 15, 2002; 100(10): 3681 - 3689. [Abstract] [Full Text] [PDF]

				W. Zeng, S. Ghosh, Y. F. Lau, L. E. Brown, and D. C. Jackson Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines J. Immunol., November 1, 2002; 169(9): 4905 - 4912. [Abstract] [Full Text] [PDF]

				C. Olive, M. R. Batzloff, A. Horvath, A. Wong, T. Clair, P. Yarwood, I. Toth, and M. F. Good A Lipid Core Peptide Construct Containing a Conserved Region Determinant of the Group A Streptococcal M Protein Elicits Heterologous Opsonic Antibodies Infect. Immun., May 1, 2002; 70(5): 2734 - 2738. [Abstract] [Full Text] [PDF]